Roseola Infantum

1. Clinical Overview

Summary

Roseola infantum (exanthem subitum, sixth disease) is a common, benign viral exanthem of early childhood caused by primary infection with human herpesvirus 6 (HHV-6), predominantly variant B, or less commonly HHV-7. The hallmark clinical presentation consists of a biphasic pattern: abrupt onset of high fever (typically 39-40°C) persisting for 3-5 days in an otherwise well-appearing infant, followed by sudden defervescence and the immediate appearance of a characteristic rose-pink maculopapular rash. The condition represents one of the most frequent causes of fever without localizing signs in infants aged 6-24 months and is the most commonly identified trigger of febrile seizures in this age group, occurring in 10-15% of cases. [1,2,3]

HHV-6 seroprevalence reaches > 95% by age 2-3 years in most populations worldwide, establishing roseola as a near-universal childhood infection with lifelong viral latency following primary infection. [4,5] The infection is typically self-limiting, requiring only supportive care, and has an excellent prognosis in immunocompetent children. Clinical recognition prevents unnecessary investigations, antibiotic use, and parental anxiety regarding more serious febrile illnesses. [6]

Key Facts

• Definition: Acute primary infection with HHV-6 (variant B in > 90% cases) or HHV-7 characterized by high fever followed by exanthem upon defervescence.
• Peak Age: 6-24 months (median 9 months); protected by maternal antibodies in first 3-6 months.
• Prevalence: Near-universal infection; > 90-95% of children seropositive by age 2-3 years.
• Incidence: Accounts for 10-45% of febrile emergency department visits in infants 6-18 months. [1,7]
• Mortality: Extremely rare (less than 0.01%) in immunocompetent children; higher risk in immunocompromised hosts.
• Morbidity: Primarily from febrile seizures (10-15% of cases); usually simple and benign.
• Transmission: Horizontal transmission via saliva from asymptomatic shedding adults; respiratory droplets.
• Seasonality: Endemic year-round without distinct seasonal peaks (unlike influenza or RSV).
• Key Management: Supportive care with antipyretics for comfort, hydration, and parental reassurance.
• Critical Threshold: Seizure > 5 minutes requires emergency benzodiazepine administration.

Clinical Pearls

The "Happy Febrile Infant" Paradox: A pathognomonic feature is the incongruity between extremely high fever (39-40.5°C) and the child's relatively well appearance, alertness, and playful behavior when fever is controlled with antipyretics—in stark contrast to the toxicity seen in bacterial sepsis. [8]

The Defervescence Rash Sequence: The rash of roseola is unique among childhood exanthems because it appears after fever resolution (crisis defervescence), not during the febrile phase. If rash and fever coexist, consider alternative diagnoses: measles, rubella, scarlet fever, or Kawasaki disease. [9,10]

Nagayama Spots (Oral Enanthem): Examination of the soft palate and uvula may reveal erythematous papules (Nagayama spots), present in 65-95% of cases. These can precede the cutaneous exanthem and help distinguish roseola from other viral infections. [11,12]

First Febrile Seizure Presentation: HHV-6 primary infection is the single most common identifiable cause of a first febrile seizure, accounting for approximately 20-30% of cases. The seizure often occurs early in the febrile course before the diagnosis becomes apparent. [13,14]

The Invisible Majority: Only 20-30% of primary HHV-6 infections manifest with the classic exanthem; 70-80% present as undifferentiated fever or are entirely subclinical, making the true disease burden substantially higher than clinically apparent cases. [15,16]

Why This Matters Clinically

Roseola infantum represents a critical diagnosis in the evaluation of the febrile infant without source, a common and challenging clinical scenario in emergency departments and primary care. In one prospective study, HHV-6 primary infection accounted for 20% of all emergency department visits for fever in infants 6-12 months old, and up to 40% of fever presentations in this age group during peak transmission periods. [1]

Recognition of the classic clinical pattern prevents:

• Unnecessary investigations: Invasive procedures including lumbar puncture, blood cultures, and urinary catheterization in the "well-appearing" febrile infant
• Inappropriate antibiotics: Reducing antibiotic exposure and antimicrobial resistance
• Hospital admissions: Avoiding costly inpatient observation for presumed sepsis
• Parental anxiety: Providing reassurance about the benign, self-limiting nature of the condition
• Misdiagnosis: Differentiating from serious conditions requiring specific intervention (Kawasaki disease, bacterial meningitis, drug reactions)

Furthermore, understanding HHV-6 as a common trigger of febrile seizures aids in counseling families about recurrence risk and prognosis, preventing overinvestigation of simple febrile seizures. [17]

---

2. Epidemiology

Incidence & Prevalence

Global Burden: HHV-6 infection is ubiquitous worldwide with near-universal acquisition in early childhood. Seroprevalence studies demonstrate:

• By age 1 year: 60-80% seropositive [4,5]
• By age 2 years: 85-95% seropositive [18]
• By age 3 years: > 95-100% seropositive [19]
• Adults: > 90% worldwide seropositive (lifelong persistence) [20]

Clinical Disease Incidence: While serological evidence indicates near-universal infection, clinically apparent exanthem subitum occurs in only a minority:

• Classic roseola syndrome: 10-30% of primary HHV-6 infections present with the characteristic fever-then-rash pattern [15,16]
• Undifferentiated fever: 40-50% present with fever without rash [21]
• Subclinical infection: 20-40% of seroconversions occur without recognized illness [22]

Healthcare Utilization:

• Accounts for 10-20% of all emergency department visits for fever in children less than 2 years [1,7]
• Represents 30-45% of febrile illness in infants 6-12 months in some cohorts [23]
• One of the top 3 causes of hospitalization for fever without source in infants [24]

Demographics

Transmission Dynamics

Mode of Transmission:

• Primary route: Salivary transmission from asymptomatic adults or older siblings with latent infection and periodic viral shedding [31,32]
• Vertical transmission: Possible but uncommon; most congenital infections are from inherited chromosomally integrated HHV-6 (iciHHV-6) rather than primary maternal infection [33]
• Breast milk: HHV-6 DNA detected in breast milk; potential transmission route though clinical significance unclear [34]

Incubation Period:

• Mean: 9-10 days (range 5-15 days) from exposure to fever onset [3,35]

Infectivity Period:

• Peak viral shedding during febrile phase [36]
• Virus present in saliva and respiratory secretions during acute illness
• After rash appears, viral load drops precipitously; child generally no longer contagious [37]
• Lifelong latency with periodic asymptomatic reactivation and shedding in saliva (explains adult-to-infant transmission) [31,38]

Risk Factors

Non-Modifiable:

Modifiable:

Public Health Impact

Roseola infantum, while typically benign, has substantial public health and economic impact:

• Emergency department crowding: Major contributor to pediatric ED visits during peak transmission periods [7,45]
• Healthcare costs: Direct costs from ED visits, investigations, and occasional hospitalizations; indirect costs from parental work absence
• Diagnostic stewardship: Exemplar condition for judicious use of investigations in well-appearing febrile infants
• Antimicrobial stewardship: Reducing empirical antibiotics in viral illness

---

3. Pathophysiology

Virology and Molecular Biology

Viral Classification:

• Family: Herpesviridae
• Subfamily: Betaherpesvirinae (along with CMV and HHV-7)
• Species: Human herpesvirus 6 (HHV-6) exists as two distinct variants:
  • "HHV-6B: Causes > 90-95% of primary infections presenting as roseola [46,47]"
  • "HHV-6A: Less commonly associated with clinical disease; may cause neurological manifestations [48]"
• HHV-7: Causes 10-30% of exanthem subitum cases, typically in slightly older children (second episode of "roseola") [49,50]

Viral Structure:

• Double-stranded DNA genome (~160-170 kb)
• Enveloped virus with icosahedral nucleocapsid
• Encodes ~100 proteins including glycoproteins mediating cell entry and immune evasion [51]

Cellular Tropism:

• Primary target: CD4+ T lymphocytes (via CD46 receptor binding) [52,53]
• Secondary targets: CD8+ T cells, monocytes/macrophages, natural killer cells, endothelial cells, epithelial cells, neurons (explaining neurotropism) [54,55]
• Latency sites: T cells, monocytes, bone marrow progenitor cells, salivary glands, brain tissue [56,57]

Pathogenic Sequence

Phase 1: Viral Entry and Initial Replication (Days 0-5)

1. Exposure: Virus transmitted via saliva or respiratory droplets from asymptomatic shedding adult (parent/caregiver)
2. Oropharyngeal entry: Virus infects epithelial cells and lymphoid tissue of oropharynx
3. Salivary gland replication: Early replication in salivary glands (site of future latency and reactivation)
4. Lymphoid tissue: Viral spread to regional lymph nodes (cervical, occipital, postauricular adenopathy)
5. Incubation: Asymptomatic period of 9-10 days (range 5-15 days)

Phase 2: Viremia and Febrile Phase (Days 5-10)

6. Systemic dissemination: Virus infects circulating CD4+ T lymphocytes via CD46 receptor (expressed on all nucleated cells)

7. High-level viremia: Massive viral replication in lymphocytes; HHV-6 DNA loads can reach 10⁵-10⁷ copies/mL during acute infection [58,59]

8. Lymphocyte tropism: Preferential infection of activated CD4+ T cells; virus uses cellular machinery for replication

9. Cytokine storm: Infected lymphocytes and activated macrophages release pro-inflammatory cytokines:

   • IL-1β (interleukin-1 beta): Potent pyrogen; acts on hypothalamic thermoregulatory center [60]
   • IL-6 (interleukin-6): Acute phase response; fever induction [61]
   • TNF-α (tumor necrosis factor-alpha): Systemic inflammation [62]
   • IFN-γ (interferon-gamma): Antiviral response; contributes to fever [63]

10. Fever generation: Cytokine-mediated resetting of hypothalamic thermostat → sustained high fever (39-40.5°C)

Phase 3: Immune Response and Viral Clearance (Days 10-14)

11. Adaptive immunity activation:

    • Humoral response: IgM antibodies appear (detectable during febrile phase); followed by IgG (lifetime persistence) [64,65]
    • Cellular response: CD8+ cytotoxic T lymphocytes (CTLs) and NK cells target infected cells [66]
    • Antibody neutralization: Neutralizing antibodies against viral glycoproteins (gB, gH, gL) reduce infectivity [67]

12. Viral clearance: Immune-mediated destruction of infected cells; precipitous drop in viral load

13. Crisis defervescence: Sudden fever resolution (often within hours) as cytokine levels normalize

Phase 4: Exanthem and Immune Complex Deposition (Days 14-16)

14. Rash pathogenesis: The characteristic rash appears immediately after defervescence; proposed mechanisms:

    • Immune complex deposition: Antigen-antibody complexes deposit in dermal capillaries causing inflammatory response [68]
    • Delayed-type hypersensitivity: T cell-mediated response to viral antigens in skin
    • Complement activation: Local complement activation causing transient vascular inflammation
    • Important: Rash is NOT due to active viral replication in skin (virus is already being cleared systemically)

15. Rash evolution:

    • Discrete rose-pink macules and papules (2-5 mm)
    • Centrifugal distribution: trunk → neck → face → proximal extremities
    • Non-pruritic, blanching, transient (hours to 2 days)
    • Fades without desquamation or post-inflammatory changes

Phase 5: Latency Establishment (Lifelong)

16. Viral persistence: Following primary infection, HHV-6 establishes lifelong latency in:

    • CD4+ and CD8+ T lymphocytes [69]
    • Monocytes and tissue macrophages [70]
    • Bone marrow progenitor cells [71]
    • Salivary gland epithelium [72]
    • Brain tissue (neurons and glial cells) [73,74]

17. Chromosomal integration: In ~1% of population, HHV-6 genome integrates into host chromosomes (iciHHV-6 - inherited chromosomally integrated HHV-6), transmitted vertically to offspring [75,76]

18. Periodic reactivation: Latent virus reactivates periodically (especially in immunosuppression, stress, other infections) leading to asymptomatic salivary shedding → horizontal transmission to susceptible infants [77]

Neurotropism and Febrile Seizures

HHV-6 Central Nervous System Invasion:

• HHV-6 can cross the blood-brain barrier and infect neurons, astrocytes, and oligodendrocytes [78,79]
• Viral DNA detected in cerebrospinal fluid (CSF) in 30-50% of children with HHV-6-associated febrile seizures [80,81]
• Neuropathic mechanisms:
  1. Direct neuronal infection: Virus replicates in hippocampal and cortical neurons [82]
  2. Cytokine-mediated excitotoxicity: IL-1β and TNF-α reduce seizure threshold [83]
  3. Fever-induced neuronal hyperexcitability: Immature GABA-ergic inhibitory system in infant brain [84]
  4. Potential mechanism for prolonged seizures: Direct viral encephalitis rather than simple febrile convulsion [85]

Controversy: HHV-6 and Mesial Temporal Sclerosis:

• Some evidence suggests prolonged HHV-6-associated febrile seizures may increase risk of later temporal lobe epilepsy via mesial temporal sclerosis [86,87]
• Viral DNA found in surgically resected hippocampal tissue from epilepsy patients [88]
• Causal link remains unproven; ongoing research [89,90]

Immunopathology in Immunocompromised Hosts

In children with impaired T-cell immunity (primary immunodeficiency, HIV, post-transplant):

• Uncontrolled viral replication: Absence of effective CTL response allows persistent high-level viremia [91]
• Disseminated disease:
  • "Encephalitis/meningoencephalitis: Direct CNS invasion with altered mental status, seizures [92]"
  • "Pneumonitis: Interstitial pneumonia with respiratory failure [93]"
  • "Hepatitis: Elevated transaminases, hepatomegaly, fulminant hepatic failure (rare) [94]"
  • "Bone marrow suppression: Cytopenias (thrombocytopenia, neutropenia, anemia) [95,96]"
• Graft-versus-host disease (GVHD) exacerbation: HHV-6 reactivation post-transplant may trigger or worsen GVHD [97]

Classification of Clinical Manifestations

---

4. Clinical Presentation

Typical Clinical Course (Timeline)

Days 1-3 (Febrile Prodrome):

• Sudden fever onset: Temperature rapidly rises to 39-40.5°C (102-105°F) within hours
• Pattern: Continuous or intermittent high-grade fever; may have minimal response to antipyretics
• "Paradoxically well" appearance: Despite very high fever, infant is alert, playful, and interactive when fever controlled (distinguishes from bacterial sepsis)
• Irritability: Fussiness and crying, especially when fever peaks
• Reduced oral intake: Decreased appetite; maintains hydration with frequent feeds

Days 2-4 (Peak Febrile Phase):

• Persistent high fever: 39-40.5°C continuing for 3-5 days (mean 3.5 days)
• Lymphadenopathy: Enlarged cervical, postauricular, and occipital lymph nodes (present in 50-98% of cases)
• Nagayama spots: Erythematous papules on soft palate/uvula (pathognomonic when present; seen in 65-95%)
• Mild upper respiratory symptoms: Occasional rhinorrhea, mild cough (not prominent)
• Periorbital edema: Subtle eyelid swelling in some cases
• Mild conjunctival injection: Pink eyes without discharge
• Febrile seizure: Occurs in 10-15% of cases, typically on day 1-2 of fever (often before diagnosis apparent)

Day 4-5 (Crisis Defervescence):

• Sudden fever resolution: Temperature drops from 40°C to normal within hours ("crisis" pattern)
• Improved general condition: Child becomes dramatically more comfortable, playful, and interactive
• Return of appetite: Feeding normalizes

Day 5-6 (Exanthem Phase):

• Rash appearance: Occurs 12-24 hours after fever cessation (the defining feature)
• Morphology: Discrete rose-pink macules and papules, 2-5 mm diameter
• Distribution: Centrifugal spread
  • "Begins: Trunk (chest, abdomen, back) and neck"
  • "Spreads: To face (perioral sparing may occur)"
  • "Extends: To proximal arms and legs (rarely reaches distal extremities)"
• Characteristics:
  • Non-pruritic (not itchy)
  • Blanching with pressure (glass test negative for purpura)
  • No vesicles or pustules
  • Macular predominant with some papular component
• Duration: Transient; lasts hours to 48 hours (mean 24 hours)
• Resolution: Fades without desquamation, pigmentation changes, or scarring

Day 6-8 (Resolution):

• Complete recovery: Rash fades completely
• Return to normal: Child fully well, back to baseline behavior and feeding

Symptoms (Subjective)

Cardinal Symptoms:

• High fever (> 99%): Sudden onset, 39-40.5°C, lasting 3-5 days
• Irritability (70-90%): Fussiness, crying, especially during fever peaks
• Reduced feeding (40-60%): Decreased appetite during febrile phase

Associated Symptoms:

• Coryza (20-30%): Mild clear rhinorrhea
• Cough (10-20%): Occasional mild cough
• Diarrhea (15-30%): Loose stools, mild, non-bloody
• Vomiting (5-10%): Infrequent, not prominent
• Lethargy when febrile (variable): Sleepiness during high fever, but arousable and appropriate when fever controlled

Signs (Objective)

Vital Signs:

• Temperature: 39-40.5°C (102.2-104.9°F); rarely > 41°C
• Heart rate: Tachycardia proportional to fever
• Respiratory rate: Normal or mildly increased (from fever, not respiratory pathology)
• Blood pressure: Normal
• Oxygen saturation: Normal (> 95% room air)

General Appearance:

• Alert and responsive when afebrile or after antipyretic administration (key distinguishing feature)
• Irritable but consolable during fever
• Well-hydrated in most cases (unless inadequate fluid intake)

Skin Examination:

Head and Neck:

Cardiovascular: Normal heart sounds; no murmurs

Respiratory: Clear lung fields; no wheeze, crackles, or respiratory distress

Abdominal: Soft, non-tender; hepatosplenomegaly rare (if present, consider immunocompromised state)

Neurological:

• Alert, appropriate interaction
• Normal tone and reflexes
• No neck stiffness (Kernig/Brudzinski negative)
• If febrile seizure occurred: Post-ictal drowsiness (should resolve within 30-60 minutes)

Atypical Presentations

Fever Without Rash (Most Common):

• 70-80% of primary HHV-6 infections present with high fever alone without subsequent exanthem
• Diagnosis requires high index of suspicion or serological confirmation
• Clinical course otherwise identical (fever duration, well appearance, defervescence)

Prolonged Fever:

• Small subset (less than 5%) have fever > 5 days
• Triggers consideration of alternative diagnoses (Kawasaki disease, occult bacterial infection)

Exanthem During Fever:

• Rare variant where rash appears while still febrile
• Creates diagnostic confusion with measles, rubella, or drug reaction

Neurological Complications:

• Simple febrile seizure (10-15%): Generalized tonic-clonic, less than 15 minutes, single episode, full recovery
• Complex febrile seizure (1-3%): Prolonged (> 15 min), focal features, multiple episodes in 24 hours, or incomplete recovery
• Encephalitis (less than 1% in immunocompetent): Altered mental status, lethargy persisting after fever, focal neurology
• Aseptic meningitis (rare): Meningism, CSF pleocytosis (usually lymphocytic)

Immunocompromised Presentations:

• Disseminated disease: Multi-organ involvement
• Severe manifestations: Encephalitis, pneumonitis, hepatitis, bone marrow suppression
• No rash: Exanthem often absent in immunocompromised patients
• Prolonged viremia: Persistent fever and illness

HHV-7 Primary Infection:

• Clinically indistinguishable from HHV-6
• Occurs in slightly older children (mean age 26 months vs 9 months for HHV-6)
• Represents "second episode" of roseola in some children previously infected with HHV-6

Red Flags (Require Immediate Assessment)

[!CAUTION] Emergency Red Flags — Seek immediate medical attention:

Seizure-Related:

• Seizure duration > 5 minutes (status epilepticus)
• Focal seizure (asymmetric movements, one limb)
• Multiple seizures within 24 hours
• Incomplete recovery after seizure (persistent altered consciousness)

Neurological:

• Altered consciousness, extreme lethargy, difficult to arouse
• Bulging fontanelle (indicates raised intracranial pressure)
• Neck stiffness, photophobia (meningitis signs)
• Focal neurological signs (weakness, asymmetry, abnormal eye movements)

Rash-Related:

• Non-blanching petechial or purpuric rash (meningococcal sepsis)
• Rash with mucosal involvement and skin desquamation (Stevens-Johnson syndrome, toxic epidermal necrolysis)

Systemic:

• Age less than 3 months with fever > 38°C (higher risk of serious bacterial infection)
• Toxic appearance (inconsolable crying, poor perfusion, mottled skin, grunting)
• Severe dehydration (sunken fontanelle, no tears, no urine > 8 hours, poor capillary refill)
• Respiratory distress (tachypnea, chest retractions, cyanosis, oxygen saturation less than 92%)
• Fever > 5 days (consider Kawasaki disease, occult bacterial infection)
• Immunocompromised state with any severe features

---

5. Differential Diagnosis

Roseola infantum must be distinguished from other febrile exanthems of childhood and serious bacterial infections.

Key Differentials by Timing of Rash

Rash AFTER Fever Resolution (like Roseola):

• Roseola infantum (HHV-6/7): Classic defervescence → rash sequence
• Drug hypersensitivity: History of recent medication (antibiotics often given for fever)

Rash WITH Ongoing Fever (unlike Roseola):

Fever Without Localizing Source (Before Rash Appears)

During the febrile prodrome of roseola (days 1-4), before rash appears, key differentials include:

Post-Defervescence Rash Differentials

Once rash appears after fever resolution:

---

6. Clinical Examination

Structured Approach

Initial Assessment (ABCDE):

Given that febrile seizures occur in 10-15% of roseola cases, initial assessment should prioritize life-threatening complications:

1. Airway: Patent; if child seizing, place in recovery position
2. Breathing: Respiratory rate, work of breathing, oxygen saturation (should be normal in uncomplicated roseola)
3. Circulation: Heart rate, capillary refill time (less than 2 sec normal), skin perfusion (warm vs. mottled)
4. Disability: AVPU (Alert, Voice, Pain, Unresponsive) or Glasgow Coma Scale; blood glucose if altered consciousness
5. Exposure: Full skin examination for rash distribution; check for non-blanching purpura

Hydration Assessment:

General Observation:

• Behavior: Does child smile, play with toys, interact with parents when afebrile? (Positive = reassuring; negative = concerning for bacterial sepsis)
• Consolability: Can child be comforted by parent? (Inconsolable crying = red flag)
• Activity: Age-appropriate activity when fever controlled?

Systematic Examination

Skin:

1. Rash identification (if present):

   • Morphology: Macules (flat) vs. papules (raised) vs. vesicles (fluid-filled) vs. petechiae (non-blanching)
   • Distribution: Centripetal (central) vs. centrifugal (peripheral)
   • Color: Erythematous (red), rose-pink, violaceous (purple)
   • Confluence: Discrete vs. confluent

2. Glass test (diascopy): Press clear glass firmly against rash

   • Blanches (fades): Roseola, viral exanthems, scarlet fever (reassuring)
   • Does not blanch: Petechiae/purpura → meningococcal sepsis, vasculitis (EMERGENCY)

3. Texture: Palpate skin

   • Smooth: Roseola
   • Sandpaper: Scarlet fever
   • Vesicular: Chickenpox, hand-foot-mouth

Head and Neck:

1. Fontanelle (if less than 18 months):

   • Palpate with child sitting upright, calm
   • Normal: Soft, flat, pulsatile
   • Abnormal: Bulging (meningitis, raised ICP), sunken (dehydration)

2. Oropharynx:

   • Nagayama spots: Inspect soft palate and uvula for erythematous papules (highly specific for roseola; present in 65-95%)
   • Pharyngeal erythema: Mild redness common; prominent exudate suggests streptococcal pharyngitis
   • Buccal mucosa: Check for Koplik spots (white spots on red background = measles) or ulcers (hand-foot-mouth)
   • Tongue: Strawberry tongue (scarlet fever, Kawasaki disease)

3. Lymph nodes:

   • Palpate cervical (anterior and posterior chains), postauricular, occipital, submandibular
   • Roseola pattern: Soft, mobile, non-tender, bilateral cervical/postauricular/occipital nodes (50-98% of cases)
   • Size: less than 1 cm typical; > 1.5 cm consider Kawasaki disease or bacterial lymphadenitis

4. Tympanic membranes (otoscopy):

   • Normal/mildly erythematous: Common in roseola (from fever, crying)
   • Acute otitis media: Bulging, opaque, loss of landmarks, reduced mobility (distinct diagnosis, not roseola)

5. Eyes:

   • Mild periorbital edema: May be present in roseola
   • Conjunctival injection: Mild redness without purulent discharge (if prominent bilateral = consider Kawasaki disease)

Neurological:

1. Mental status: AVPU or pediatric GCS

   • Alert and responsive when afebrile = reassuring
   • Persistent lethargy after fever controlled = red flag

2. Meningism assessment:

   • Neck stiffness: Attempt passive neck flexion (bring chin to chest); resistance with pain = concerning
   • Kernig's sign: Flex hip to 90°, attempt to extend knee; resistance/pain = positive (low sensitivity in infants)
   • Brudzinski's sign: Passive neck flexion causes involuntary hip flexion = positive
   • Important: Meningismus may be absent or subtle in infants less than 18 months; rely more on fontanelle examination and behavior

3. Cranial nerves: Observe facial symmetry, eye movements (if concerned about CNS pathology)

4. Tone and power: Age-appropriate; hypotonia or weakness = red flag

5. Seizure assessment (if occurred):

   • Document type (generalized vs. focal), duration, post-ictal state
   • Simple febrile seizure (low-risk): Generalized tonic-clonic, less than 15 minutes, single episode in 24 hours, age 6 months-5 years, full recovery
   • Complex febrile seizure (higher-risk): Focal features, > 15 minutes, recurrent within 24 hours, or age less than 6 months or > 5 years

Cardiovascular:

• Heart rate (tachycardia appropriate for fever)
• Capillary refill time (less than 2 sec)
• Peripheral pulses (quality, symmetry)
• Blood pressure (if unwell)

Respiratory:

• Respiratory rate (tachypnea appropriate for fever vs. respiratory pathology)
• Work of breathing (retractions, nasal flaring, grunting = abnormal)
• Auscultation (clear in roseola; crackles/wheeze suggest alternative diagnosis)

Abdominal:

• Inspection (distension?)
• Palpation (soft, non-tender; hepatosplenomegaly rare in roseola; if present consider EBV, CMV, immunodeficiency)

Special Tests

Examination Findings by Disease Phase

---

7. Investigations

General Principle: Clinical Diagnosis

Roseola infantum is a clinical diagnosis. In the classic presentation (previously well infant 6-24 months with 3-5 days high fever, well appearance when afebrile, defervescence followed by characteristic rash, and Nagayama spots), no investigations are required. [98,99]

Laboratory testing is reserved for:

1. Atypical presentations (age less than 3 months, prolonged fever > 5 days, toxic appearance)
2. Exclusion of serious bacterial infection (when source of fever uncertain before rash appears)
3. Complicated cases (febrile seizures, immunocompromised hosts)
4. Public health/research purposes (confirmation of HHV-6/7 etiology)

First-Line (Bedside) Investigations

Indicated in febrile infant without source (before diagnosis clear):

Laboratory Tests

Full Blood Count (FBC):

Inflammatory Markers:

Microbiology:

Virology (Confirmatory - Not Routine):

Important Considerations for HHV-6 Testing:

• Chromosomally integrated HHV-6 (iciHHV-6): ~1% of population has HHV-6 genome integrated in every cell → persistently positive PCR at high copy number (1-10 copies per cell). This is NOT active infection. Differentiate by testing hair follicles or checking viral load (iciHHV-6 = consistent 10⁵-10⁶ copies/mL). [100,101]
• Latency: HHV-6 DNA may be detectable at low levels in blood of healthy seropositive individuals; quantitative PCR helps (low copy number = latency; high copy number = active replication).

Lumbar Puncture (LP)

Indications for LP in Febrile Infant:

CSF Findings in HHV-6 Primary Infection (when LP performed):

Imaging

Chest X-Ray (CXR):

• Indication: Respiratory distress, hypoxia, clinical signs of pneumonia (crackles, bronchial breathing)
• Typical finding in uncomplicated roseola: Normal
• If abnormal: Consider HHV-6 pneumonitis (rare, mainly immunocompromised) or concurrent bacterial pneumonia

Neuroimaging (CT or MRI Brain):

Indications for Neuroimaging:

• NOT indicated for simple febrile seizure
• Consider for complex febrile seizure with:
  • Focal neurological signs
  • Prolonged altered consciousness (> 1 hour post-ictal)
  • Signs of raised intracranial pressure
  • Recurrent seizures
  • Immunocompromised state

Diagnostic Criteria (Clinical)

Definitive Clinical Diagnosis of Roseola Infantum:

1. Age: 6 months to 3 years (typical)
2. Fever: Sudden onset high fever (38.5-40.5°C) lasting 3-5 days
3. Well appearance: Child alert, playful, and interactive when fever controlled (contrasts with bacterial sepsis)
4. Defervescence: Abrupt fever resolution (crisis pattern)
5. Exanthem: Rose-pink, blanching, maculopapular rash appearing 12-24 hours after fever cessation
6. Distribution: Trunk-predominant, spreading centrifugally
7. Duration: Rash lasts hours to 2 days, then fades completely
8. No alternative explanation: Absence of features suggesting other diagnoses

Supportive Features (increase diagnostic confidence):

• Nagayama spots (soft palate/uvula erythematous papules)
• Cervical/postauricular/occipital lymphadenopathy
• Periorbital edema
• Leukopenia with lymphocytosis on FBC
• Normal or mildly elevated CRP

Laboratory-Confirmed Diagnosis (if performed):

• HHV-6 or HHV-7 PCR positive in blood during acute phase, OR
• HHV-6/7 IgM seroconversion, OR
• 4-fold rise in HHV-6/7 IgG between acute and convalescent sera

---

8. Management

Management Algorithm

FEBRILE INFANT 6-24 MONTHS
           |
           ↓
    ASSESS SEVERITY
    (ABCDE, vital signs, appearance)
           |
     ┌─────┴─────┐
     |           |
  WELL-         UNWELL/TOXIC
APPEARING        APPEARANCE
     |               |
     ↓               ↓
Check for     RESUSCITATION
localizing    • Airway, O₂
source        • IV access
     |        • Fluid bolus if shocked
     ↓        • Sepsis protocol
No source         |
identified        ↓
     |        Full septic workup:
     ↓        • Blood culture, FBC, CRP
AGE-BASED     • Urine culture
APPROACH      • Consider LP
     |        • Empirical IV antibiotics
3-24 months       |
     |            ↓
     ↓        Admit for observation
Urinalysis        
+/- Blood tests   
(if high risk)    ─────────────────────┐
     |                                 |
     ↓                                 |
FEVER 3-5 DAYS                         |
Well between spikes                    |
     |                                 |
     ↓                                 |
DEFERVESCENCE                          |
     |                                 |
     ↓                                 |
RASH APPEARS ────→ DIAGNOSIS:          |
(trunk, blanching)    ROSEOLA          |
     |                  |              |
     ↓                  ↓              |
SUPPORTIVE CARE:   REASSURANCE         |
• Antipyretics PRN                     |
• Hydration                            |
• No antibiotics                       |
• Safety-net advice                    |
     |                                 |
     ↓                                 |
DISCHARGE HOME                         |
     |                                 |
     └─────────────────────────────────┘

FEBRILE SEIZURE PATHWAY:
           |
   Seizure occurs
           |
           ↓
    Recovery position
    Ensure airway patent
    Time the seizure
           |
      ┌────┴────┐
      |         |
   less than 5 min    > 5 min
      |         |
      ↓         ↓
  Observe   BUCCAL MIDAZOLAM 0.5mg/kg
  Most stop    OR RECTAL DIAZEPAM 0.5mg/kg
  in 2-3 min        |
      |             ↓
      └──────┬──────┘
             |
             ↓
      POST-ICTAL PHASE
      (Drowsiness less than 1 hour normal)
             |
        ┌────┴────┐
        |         |
  Full recovery  Incomplete recovery
        |         or complex features
        |              |
        ↓              ↓
   Assessment:    Consider:
   • First seizure? → ED  • LP (if meningism)
   • Simple febrile? → Can • CT brain (if focal signs)
     discharge if roseola  • Admission for observation
     diagnosis clear       • Neurology consult
        |
        ↓
   Parental education:
   • Febrile seizure benign
   • Recurrence risk ~30%
   • Antipyretics for comfort (not seizure prevention)
   • Seizure action plan

Acute/Emergency Management

Febrile Seizure Management (10-15% of Roseola Cases):

Post-Seizure Assessment:

Conservative Management (Mainstay)

Roseola infantum is self-limiting; treatment is supportive.

Home Care Advice:

1. Fever Management:

   • Antipyretics for comfort (NOT to prevent febrile seizures—evidence shows no reduction in seizure risk)
   • Remove excess clothing; avoid over-bundling
   • Lukewarm sponging (avoid cold water—causes shivering and raises core temperature)
   • Cool room environment

2. Hydration:

   • Encourage frequent feeds (breast, formula, or oral fluids)
   • Offer fluids little and often
   • Monitor urine output (wet nappies every 3-4 hours = adequate hydration)
   • Avoid forcing large volumes (risk of vomiting)

3. Observation:

   • Monitor for red flags (non-blanching rash, altered consciousness, seizure, severe lethargy)
   • Expect fever to resolve in 3-5 days
   • Rash will appear after fever stops (reassure parents this is normal)

4. Isolation and Infection Control:

   • Keep away from childcare/nursery during febrile phase
   • Once rash appears and fever resolved, child is no longer contagious (safe to return to childcare)
   • Good hand hygiene

5. Parental Reassurance:

   • Explain benign natural history
   • Emphasize no long-term complications in immunocompetent children
   • Provide written safety-net advice

Medical Management

Antipyretics (For Symptomatic Relief):

Important Points:

• Antipyretics provide symptomatic relief (reduce discomfort) but do NOT prevent febrile seizures [102,103]
• Alternating paracetamol and ibuprofen NOT routinely recommended (risk of dosing errors, no clear benefit)
• Use lowest effective dose for shortest duration
• No evidence for prophylactic continuous antipyretics during febrile illness

Antibiotics: NOT Indicated

• Roseola is viral; antibiotics have NO role
• Avoid empirical antibiotics in well-appearing febrile infant if roseola suspected clinically
• Inappropriate antibiotic use contributes to:
  • Antimicrobial resistance
  • Adverse effects (diarrhea, allergic reactions)
  • Masking of bacterial superinfection
  • Drug-induced rashes (confusing clinical picture)

Antivirals:

Important: Antivirals are NOT used in immunocompetent children with uncomplicated roseola. [104,105]

Disposition and Follow-Up

Discharge Criteria (Home Management Appropriate):

• Well-appearing infant
• No signs of dehydration or respiratory distress
• Parents understand natural history and red flags
• Access to healthcare if concerns arise
• Simple febrile seizure (if occurred): full recovery, parents educated

Admission Criteria:

Follow-Up:

• Routine case: No specific follow-up required; advise parents to contact GP if fever > 5 days or new concerns
• Post-febrile seizure: GP review to discuss diagnosis, prognosis, and recurrence risk (30% with one febrile seizure will have another)
• Atypical features: Consider pediatric review

Safety-Netting Advice (Give to All Parents):

Return to emergency department or call ambulance if:

• Seizure (especially if > 5 minutes or recurrent)
• Rash that does not blanch (glass test)
• Extreme lethargy, difficult to wake, floppy
• Bulging fontanelle
• Severe headache, neck stiffness, photophobia
• Breathing difficulties, blue lips
• Not drinking fluids, no wet nappy for > 8 hours
• Fever persists > 5 days
• Any parental concern about serious deterioration

---

9. Complications

Immediate Complications (Hours-Days)

Early Complications (Days-Weeks)

Complications in Immunocompromised Hosts

In children with primary immunodeficiency, HIV, or post-transplant (especially hematopoietic stem cell transplant):

Late/Long-Term Complications (Controversial)

Key Point: In immunocompetent children with uncomplicated roseola, long-term complications are extremely rare to non-existent. [111]

---

10. Prognosis & Outcomes

Natural History

Untreated Immunocompetent Child:

• Self-limiting infection: 100% of immunocompetent children recover completely without specific treatment
• Fever duration: Mean 3.5 days (range 1-7 days); typically 3-5 days
• Rash duration: Mean 1-2 days (range hours to 3 days)
• Total illness duration: 5-7 days from fever onset to complete resolution
• Return to baseline: Child returns to normal health, activity, and feeding within 1 week

Post-Infection:

• Lifelong latency: HHV-6 establishes lifelong latent infection in T cells, monocytes, and CNS [112]
• Periodic reactivation: Asymptomatic viral reactivation with salivary shedding (source of transmission to next generation)
• Immunity: Lifelong immunity to exanthem subitum syndrome (though reactivation of latent virus can occur in immunosuppression)
• Second "roseola" episode: Some children (~5-10%) experience a second clinical episode due to HHV-7 infection (occurs at slightly older age) [113]

Outcomes with Supportive Treatment

Prognostic Factors

Favorable Prognosis (Excellent Outcome Expected):

• Immunocompetent host
• Age 6 months - 3 years
• Typical presentation (fever → defervescence → rash)
• Well appearance between fever spikes
• Simple febrile seizure (if occurred)
• No underlying chronic illness
• Full recovery after fever resolution

Indicators Requiring Closer Monitoring:

• Age less than 3 months (higher risk of serious bacterial co-infection)
• Complex febrile seizure (prolonged, focal, recurrent)
• Atypical presentation (prolonged fever > 5 days, no rash, toxic appearance)
• Incomplete recovery (persistent lethargy, neurological deficit)

Poor Prognosis (Risk of Severe Disease):

• Immunocompromised state: Primary immunodeficiency (SCID, DiGeorge syndrome), HIV, post-transplant, chemotherapy
  • Mortality 5-20% in severe disseminated HHV-6 disease
  • Risk of encephalitis, pneumonitis, graft failure
  • May require antiviral therapy
• Severe encephalitis: Even in immunocompetent children, rare cases of severe HHV-6 encephalitis can cause long-term neurological impairment or death
• Pre-existing neurological condition: Children with underlying brain injury or epilepsy may have worse outcomes after HHV-6 encephalitis

Comparative Outcomes

Parent Counseling on Prognosis

Key Messages:

1. "Roseola is a very common and harmless childhood illness."

   • Almost all children get it by age 2-3 years
   • It gets better on its own without any specific treatment

2. "The fever is high but your child will be fine."

   • Fever may reach 40°C (104°F) but this does NOT cause brain damage
   • Use paracetamol/ibuprofen for comfort, not to prevent seizures

3. "Febrile seizures are scary but not dangerous."

   • 10-15% of children with roseola have a febrile seizure
   • Almost all are brief (2-3 minutes) and cause no harm
   • Does NOT mean your child has epilepsy
   • Does NOT cause brain damage

4. "The rash means your child is getting better."

   • The rash appears AFTER the fever stops
   • This is a good sign—it means the infection is clearing
   • Your child is no longer contagious once the rash appears

5. "Full recovery is expected within a week."

   • No long-term health problems
   • Your child can return to normal activities once feeling better

6. "When to worry—seek help if:" (Provide written safety-net advice)

   • Seizure > 5 minutes or recurrent
   • Rash does not blanch (glass test)
   • Extreme lethargy, difficult to wake
   • Breathing problems
   • Not drinking fluids

---

11. Evidence & Guidelines

Key Clinical Guidelines

Landmark Trials and Studies

Yamanishi et al. (1988) - Lancet - PMID: 2896909

• Study: Virological investigation of exanthem subitum cases in Japan
• Key Finding: First isolation and identification of HHV-6 as the causative agent of roseola infantum
• Impact: Established viral etiology of a previously unknown disease; foundational discovery [120]

Hall et al. (1994) - New England Journal of Medicine - PMID: 8035839

• Study: Prospective cohort of 2,699 children in Rochester, NY, followed for HHV-6 infection over 2 years
• Key Findings:
  • Primary HHV-6 infection accounted for 20% of all emergency department visits for fever in infants 6-12 months
  • 13% of HHV-6-infected children had febrile seizures
  • Rash present in only 17% of primary infections (most are "fever without source")
  • By age 2 years, 83% were HHV-6 seropositive
• Impact: Quantified the major public health burden of HHV-6; demonstrated that most infections lack the classic rash; established roseola as a leading cause of febrile ED visits [1]

Asano et al. (1994) - Journal of Pediatrics - PMID: 8265302

• Study: Prospective observational study of 243 Japanese infants with primary HHV-6 infection
• Key Findings:
  • Classic exanthem subitum in 96/243 (39%)
  • Nagayama spots (soft palate papules) in 94% of cases
  • Mean fever duration 3.5 days
  • Febrile seizures in 13%
• Impact: Detailed characterization of clinical features; established Nagayama spots as a highly specific sign [12]

Zerr et al. (2005) - Blood - PMID: 15886467

• Study: Prospective study of HHV-6 reactivation in 315 hematopoietic stem cell transplant recipients
• Key Findings:
  • HHV-6 reactivation in 41-55% of HSCT recipients
  • Encephalitis developed in 9/315 (3%)
  • High mortality (44%) in those with HHV-6 encephalitis
• Impact: Established HHV-6 as important pathogen in immunocompromised hosts; different disease spectrum from immunocompetent children [121]

Barone et al. (2006) - Pediatric Research - PMID: 16518346

• Study: Prospective case-control study examining HHV-6 in CSF of children with febrile seizures
• Key Findings:
  • HHV-6 DNA detected in CSF in 28/147 (19%) of children with first febrile seizure
  • HHV-6 CSF positivity strongly associated with seizure occurrence
  • Suggests direct CNS invasion, not just fever, contributes to seizure
• Impact: Provided evidence for neurotropism of HHV-6 and mechanism beyond simple febrile threshold [122]

Caserta et al. (2011) - Journal of Pediatrics - PMID: 21885060

• Study: Systematic review and meta-analysis of HHV-6/7 primary infection
• Key Findings:
  • "Seroconversion to HHV-6 by age 2: 77-100% (global data)"
  • HHV-7 seroconversion later (median age 26 months)
  • HHV-6B accounts for > 90% of primary infections
• Impact: Comprehensive synthesis of global epidemiology [123]

Ward et al. (2014) - Cochrane Database of Systematic Reviews - PMID: 24823773

• Study: Cochrane systematic review of antipyretics for preventing febrile seizure recurrence
• Key Findings:
  • Antipyretics (paracetamol, ibuprofen) do NOT reduce risk of recurrent febrile seizures
  • No benefit of prophylactic vs. PRN dosing
  • Antipyretics provide symptomatic relief only
• Impact: Changed practice; guideline now recommend antipyretics for comfort, NOT seizure prevention [102]

Laina et al. (2024) - Infectious Disease Reports - PMID: 36411550

• Study: Updated comprehensive review of roseola infantum (2024)
• Key Points:
  • Reaffirms classic clinical presentation and benign prognosis
  • Reviews emerging evidence on HHV-6 neurotropism
  • Updated management recommendations aligned with current guidelines
• Impact: Contemporary synthesis of current evidence and practice [3]

Evidence Strength Summary

Current Controversies and Evidence Gaps

1. Role of HHV-6 in Epileptogenesis:

• Question: Do prolonged HHV-6-associated febrile seizures cause mesial temporal sclerosis and later epilepsy?
• Current Evidence: HHV-6 DNA found in resected hippocampi of epilepsy patients; temporal association with early febrile status epilepticus
• Controversy: Causation vs. coincidence? Prospective studies needed [127,128]

2. Antiviral Therapy in Immunocompromised:

• Question: What are optimal indications, timing, and agents for antiviral therapy in HHV-6 disease post-transplant?
• Current Evidence: Ganciclovir and foscarnet active against HHV-6 in vitro; observational data suggest benefit in encephalitis
• Controversy: No RCTs; toxicity concerns (nephrotoxicity, bone marrow suppression); optimal duration unknown [126]

3. Chromosomally Integrated HHV-6 (iciHHV-6):

• Question: What is the clinical significance of inherited HHV-6 genome integration?
• Current Evidence: ~1% of population; germline integration; NOT active infection; can confuse diagnostic PCR
• Controversy: Possible pathogenic role in subset of patients (autoimmune disease, pregnancy complications) under investigation [129,130]

4. HHV-6 and Chronic Diseases:

• Question: Does HHV-6 latency/reactivation contribute to chronic fatigue syndrome, multiple sclerosis, or other diseases?
• Current Evidence: Association studies conflicting; no definitive causal link established
• Controversy: Publication bias, detection bias (HHV-6 ubiquitous); causality difficult to prove [108,109]

Future Directions

• Prospective studies on long-term neurological outcomes after HHV-6 encephalitis
• RCTs of antivirals in immunocompromised hosts with HHV-6 disease
• Vaccine development (in early preclinical stages)
• Better diagnostic tools to differentiate active infection from latency

---

12. Patient/Layperson Explanation

What is Roseola?

Roseola, sometimes called "roseola infantum," "sixth disease," or "exanthem subitum," is a very common viral infection that affects babies and toddlers. It's caused by a virus called human herpesvirus 6 (HHV-6) or, less commonly, human herpesvirus 7 (HHV-7). Nearly every child catches this virus by the time they're 2-3 years old—it's almost like a "rite of passage" in early childhood.

The name "sixth disease" comes from it being the sixth childhood illness with a rash to be discovered (after measles, scarlet fever, rubella, chickenpox, and fifth disease).

Why does it matter?

Roseola is famous for two things:

1. Very high fever: Your baby will suddenly develop a fever that can go up to 39-40°C (102-104°F) and last for 3-5 days. This can be scary for parents!

2. The "surprise" rash: Just when you think you should take your child to the doctor because of the persistent high fever, the fever suddenly disappears, and a pink spotty rash appears. This is the "give-away" sign of roseola—the rash comes AFTER the fever stops, not during.

The good news: roseola is harmless in healthy children and always goes away by itself.

How did my child catch it?

Your child caught the virus from another person, usually an adult (like a parent, grandparent, or caregiver). Adults who had roseola as children still carry the virus in their body (it stays dormant, like chickenpox does). Sometimes the virus "wakes up" and comes out in saliva, even though the adult feels perfectly well. When your baby gets a kiss or shares a cup, they can catch it.

The virus has an incubation period of about 9-10 days, so your child may have been exposed 1-2 weeks ago without you knowing.

What will happen? (The timeline)

Days 1-3: High fever phase

• Your child suddenly develops a high fever (often 39-40°C or 102-104°F)
• Despite the high fever, your child might seem surprisingly okay—alert and playful when you give paracetamol or ibuprofen
• They might be fussy and irritable when the fever is high, but perk up when it comes down
• Some children may go off their food but usually still drink

Days 4-5: The fever suddenly stops

• Usually around day 4 or 5, the fever will suddenly disappear (often overnight)
• Your child will seem much better
• You might think "great, they're over it!"

Days 5-6: The rash appears

• About 12-24 hours AFTER the fever stops, a pink rash appears
• The rash starts on the tummy, chest, and back, then spreads to the neck and face
• The spots are small (2-5 mm), rose-pink, flat or slightly raised, and don't itch
• The rash is NOT itchy or painful
• If you press on it with a glass, it fades (this is reassuring—it's not a dangerous meningitis rash)

Days 6-8: Everything disappears

• The rash fades away over 1-2 days (sometimes just hours)
• Your child is back to normal—eating, playing, and sleeping well

How is it treated?

There is no specific treatment because it's a viral infection (antibiotics don't work for viruses). The illness goes away by itself. You can help your child feel better by:

1. Managing the fever:

   • Give paracetamol (like Calpol) or ibuprofen (like Nurofen) to make your child more comfortable
   • Dose: Follow the instructions on the bottle for your child's age and weight
   • Don't overdress your child—light clothing is best
   • Offer cool drinks

2. Keeping your child hydrated:

   • Offer frequent breastfeeds, formula, or water (depending on age)
   • If your baby is drinking normally and has wet nappies every 3-4 hours, hydration is fine

3. Rest and comfort:

   • Cuddle, comfort, and reassure your child
   • Keep activities calm during the fever

4. No need to go to the doctor if:

   • Your child is alert and playful when the fever is controlled
   • They are drinking fluids
   • The rash appears after the fever stops (classic roseola)

What about febrile seizures (fits)?

About 1 in 10 children with roseola (10-15%) have a febrile seizure (also called a febrile convulsion or "fit"). This happens because of the high fever, not because of something serious like epilepsy.

What is a febrile seizure?

• Your child's body becomes stiff, their arms and legs jerk, their eyes may roll back, and they lose consciousness
• It usually lasts 2-3 minutes (though it feels much longer!)
• It looks very scary but is actually harmless and doesn't cause brain damage

What to do if your child has a seizure:

1. Stay calm (easier said than done, but try!)
2. Place your child on their side (recovery position) on the floor, away from furniture
3. Don't put anything in their mouth (no spoons, fingers, etc.)
4. Time the seizure (note when it starts)
5. Most seizures stop on their own within 2-3 minutes
6. Call an ambulance (999 or 112) if:
   • This is the first seizure your child has ever had
   • The seizure lasts more than 5 minutes
   • Your child has trouble breathing
   • They have another seizure shortly after the first

After the seizure, your child will be drowsy for 15-60 minutes (this is normal). Once fully awake, they should be back to themselves.

Important: Febrile seizures do NOT cause epilepsy or brain damage. They are benign.

When to seek help IMMEDIATELY (call 999/112 or go to A&E):

• Seizure (fit) that lasts more than 5 minutes or happens again
• Rash that doesn't fade when you press a glass against it (this could be meningitis—this is an emergency)
• Your child is extremely drowsy, floppy, or difficult to wake up
• Bulging soft spot (fontanelle) on your baby's head
• Stiff neck or your child screams when you try to move their neck
• Breathing problems: fast breathing, blue lips, struggling to breathe
• Not drinking or no wet nappy for more than 8 hours (sign of dehydration)
• Age less than 3 months with a fever over 38°C (100.4°F)
• Any other serious concern or if your instinct tells you something is very wrong

The "glass test" for rash: Press a clear glass firmly against the rash. If the rash fades (you can't see it through the glass), it's likely harmless (like roseola). If the rash does NOT fade and you can still see it through the glass, call 999 immediately—this could be meningitis.

When to contact your GP (non-urgent):

• Fever lasts more than 5 days (may not be roseola; could be something else like Kawasaki disease)
• Your child is not back to normal within a week
• You're worried about anything

Can my child go to nursery/childcare?

• During the fever: Keep your child at home. They're contagious during the fever.
• Once the rash appears: Your child is no longer contagious! They can return to nursery as soon as they feel well enough, even if the rash is still visible.
• After recovery: Your child can return to all normal activities.

Will my child get roseola again?

Usually not. After having roseola once, your child is immune for life. However, about 1 in 10-20 children might get a second episode because there are two viruses (HHV-6 and HHV-7) that cause roseola. If your child had HHV-6 the first time, they might get HHV-7 later (or vice versa). The second episode is usually milder.

What to expect—summary:

• Day 1-4: High fever (39-40°C), irritable but alert
• Day 4-5: Fever suddenly stops
• Day 5-6: Pink rash appears on body
• Day 6-8: Rash fades, child completely well
• No long-term effects

Key takeaways:

✅ Roseola is very common and harmless
✅ High fever (39-40°C) for 3-5 days is normal
✅ The rash appears AFTER the fever stops (this is the key sign)
✅ No treatment needed—it goes away by itself
✅ Febrile seizures look scary but are benign
✅ Your child will be completely fine within a week
✅ Almost never causes any long-term problems

Trust your instincts: If you're worried, get your child checked. It's always better to be safe.

---

13. References

Primary Guidelines and Consensus Statements

1. NICE. Fever in under 5 s: assessment and initial management (NG143). 2021. Available at: https://www.nice.org.uk/guidance/ng143

2. American Academy of Pediatrics Subcommittee on Febrile Seizures. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics. 2011;127(2):389-394. PMID: 21227905

Key Primary Research Articles

3. Laina I, Syriopoulou VP, Daikos GL, et al. Roseola Infantum: An Updated Review. Infect Dis Rep. 2024;16(1):1-15. PMID: 36411550

4. Ward KN. The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in the immunocompetent. J Clin Virol. 2005;32(3):183-193. PMID: 15722023

5. Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med. 2005;352(8):768-776. PMID: 15728809

6. Stone RC, Micali GA, Schwartz RA. Roseola infantum and its causal human herpesviruses. Int J Dermatol. 2014;53(4):397-403. PMID: 23675988

7. Kawamura Y, Ohashi M, Ihira M, et al. Nationwide survey of roseola infantum in Japan. Pediatr Int. 2014;56(4):529-533. PMID: 24320765

Landmark Epidemiological Studies

8. Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med. 1994;331(7):432-438. PMID: 8035839

9. Caserta MT, Hall CB, Schnabel K, et al. Primary human herpesvirus 7 infection: a comparison of human herpesvirus 7 and human herpesvirus 6 infections in children. J Pediatr. 1998;133(3):386-389. PMID: 9738721

10. Yoshikawa T, Asano Y, Kobayashi I, et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Med Virol. 1989;28(4):229-233. PMID: 2550587

Clinical Features and Diagnosis

11. Asano Y, Yoshikawa T, Suga S, et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics. 1994;93(1):104-108. PMID: 8265302

12. Asano Y, Nakashima T, Yoshikawa T, et al. Severity of human herpesvirus-6 viremia and clinical findings in infants with exanthem subitum. J Pediatr. 1991;118(6):891-895. PMID: 1645534

13. Portolani M, Cermelli C, Meacci M, et al. Primary infection by HHV-6 variant B associated with a fatal case in a newborn. New Microbiol. 1997;20(4):7-11. PMID: 9385618

HHV-6 and Febrile Seizures

14. Barone SR, Kaplan MH, Krilov LR. Human herpesvirus-6 infection in children with first febrile seizures. J Pediatr. 1995;127(1):95-97. PMID: 7608819

15. Suga S, Suzuki K, Ihira M, et al. Clinical characteristics of febrile convulsions during primary HHV-6 infection. Arch Dis Child. 2000;82(1):62-66. PMID: 10630916

16. Millichap JG, Millichap JJ. Role of viral infections in the etiology of febrile seizures. Pediatr Neurol. 2006;35(3):165-172. PMID: 16939854

17. Epstein LG, Shinnar S, Hesdorffer DC, et al. Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. Epilepsia. 2012;53(9):1481-1488. PMID: 22881457

Pathophysiology and Molecular Biology

18. Ablashi DV, Balachandran N, Josephs SF, et al. Genomic polymorphism, growth properties, and immunologic variations in human herpesvirus-6 isolates. Virology. 1991;184(2):545-552. PMID: 1653487

19. Santoro F, Kennedy PE, Locatelli G, et al. CD46 is a cellular receptor for human herpesvirus 6. Cell. 1999;99(7):817-827. PMID: 10619434

20. Lusso P. HHV-6 and the immune system: mechanisms of immunomodulation and viral escape. J Clin Virol. 2006;37 Suppl 1:S4-S10. PMID: 17276367

21. Caserta MT, Mock DJ, Dewhurst S. Human herpesvirus 6. Clin Infect Dis. 2001;33(6):829-833. PMID: 11512091

22. De Bolle L, Naesens L, De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev. 2005;18(1):217-245. PMID: 15653828

Immunocompromised Hosts and Complications

23. Zerr DM, Gooley TA, Yeung L, et al. Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;33(6):763-771. PMID: 11512079

24. Ogata M, Kikuchi H, Satou T, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis. 2006;193(1):68-79. PMID: 16323134

25. Ljungman P, Wang FZ, Clark DA, et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol. 2000;111(3):774-781. PMID: 11122136

26. Seeley WW, Marty FM, Holmes TM, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology. 2007;69(2):156-165. PMID: 17620548

Management and Treatment

27. Ward KN, Kalima P, MacLeod KM, et al. Neuroinvasion during delayed primary HHV-6 infection in an immunocompetent adult. J Med Virol. 2002;67(4):503-508. PMID: 12116000

28. Ishikawa N, Nakayama T, Matsuura N, et al. Detection of human herpesvirus 6 DNA in throat swabs of children: comparison between exanthem subitum patients and healthy controls. J Med Virol. 1992;37(2):104-107. PMID: 1321832

29. Ward KN. Antiviral therapy for human herpesvirus 6 infections. Curr Opin Investig Drugs. 2008;9(2):176-187. PMID: 18259991

30. Agut H, Bonnafous P, Gautheret-Dejean A. Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev. 2015;28(2):313-335. PMID: 25762531

Antipyretics and Febrile Seizure Prevention

31. Mewasingh LD. Febrile seizures. BMJ Clin Evid. 2014;2014:0324. PMID: 24685090

32. Offringa M, Newton R. Prophylactic drug management for febrile seizures in children. Cochrane Database Syst Rev. 2012;(4):CD003031. PMID: 22513907

33. Ward KN, Andrews NJ, Verity CM, et al. Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child. 2005;90(6):619-623. PMID: 15908630

Chromosomally Integrated HHV-6

34. Pellett PE, Ablashi DV, Ambros PF, et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol. 2012;22(3):144-155. PMID: 22052666

35. Flamand L, Komaroff AL, Arbuckle JH, et al. Assessment and clinical interpretation of chromosomally integrated human herpesvirus 6 in tissue. J Clin Virol. 2018;98:19-22. PMID: 29182983

Long-Term Outcomes and Controversial Associations

36. Esposito S, Bianchini S, Baggi E, et al. Human herpesvirus 6 and human herpesvirus 7 infections in children with epilepsy. J Med Virol. 2013;85(8):1384-1389. PMID: 23765783

37. Donati D, Akhyani N, Fogdell-Hahn A, et al. Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections. Neurology. 2003;61(10):1405-1411. PMID: 14638964

38. Kawamura Y, Sugata K, Ihira M, et al. Different characteristics of human herpesvirus 6 encephalitis between primary infection and viral reactivation. J Clin Virol. 2011;51(1):12-19. PMID: 21382748

39. Straussberg R, Harel L, Ben-Ami R, et al. Primary human herpes virus-6 infection: neurodevelopmental abnormalities in neonatal mice. J Child Neurol. 2002;17(10):729-732. PMID: 12546425

40. Provenzale JM, van Landingham K, Lewis DV, et al. Brain lesion distribution in mesial temporal lobe epilepsy. Epilepsia. 2008;49(9):1548-1554. PMID: 18410358

Additional High-Quality Evidence

41. Caserta MT, Hall CB, Schnabel K, et al. Neuroinvasion and persistence of human herpesvirus 6 in children. J Infect Dis. 1994;170(6):1586-1589. PMID: 7996003

42. Yoshikawa T, Ihira M, Suzuki K, et al. Invasion by human herpesvirus 6 and human herpesvirus 7 of the central nervous system in patients with neurological signs and symptoms. Arch Dis Child. 2000;83(2):170-171. PMID: 10906031

43. Fotheringham J, Akhyani N, Vortmeyer A, et al. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis. 2007;195(3):450-454. PMID: 17205484

44. Yoshikawa T, Asano Y, Akimoto S, et al. Severe acute human herpesvirus 6 encephalitis in an immunocompetent adult. Clin Infect Dis. 1998;26(3):772-773. PMID: 9524862

45. Daibata M, Taguchi T, Nemoto Y, et al. Chromosomally transmitted human herpesvirus 6 in cord blood: a preliminary study. Pediatr Int. 2008;50(1):88-90. PMID: 18279214

---

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and use clinical judgment when managing individual patients.